Q3 2025 saw just over $120M flow into psychedelics companies, with atai Life Sciences, Reunion Neuroscience, and Sensorium Therapeutics leading the way. Explore key trends, public vs. private dynamics, and how the markets are reacting to trial and regulatory news in our Q3 roundup.| Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical…| Psychedelic Alpha
Oregon Psilocybin Services (OPS) has now published its second dataset for 2025, with updates summarised in our Oregon Psilocybin Services Tracker. Here, we share a summary of the main takeaways for…| Psychedelic Alpha
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. ∎ Pα+ is read by the world’s leading drug…| Psychedelic Alpha
Work with Psychedelic Alpha’s Josh Hardman and his network of subject matter experts: from well-defined consultancy projects and regular advisory sessions through to idea development and venture…| Psychedelic Alpha
